BioSpace News Archive

Top-line results of the SPI2 trial expected by Q1 2020

Soligenix, Inc. announced today its recent accomplishments and financial results for the third quarter ended September 30, 2018.

TARIS® announced today the presentation of data detailing the natural history of patients with Muscle Invasive Bladder Cancer (MIBC) who do not receive potentially curative therapy.

Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH),

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced advancements in the company’s oncology program.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company presented updated results from the ongoing Phase 1/2 open-label extension (OLE) study of givosiran, an investigational RNAi therapeutic, targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP).

Halo Labs Inc. is pleased to report dispensary sales of approximately US$1.23 million for October 2018. This is an increase of approximately US$353,000 over September 2018. Approximately US$245,000 of the dispensary sales in October was derived from the Company’s first full month of sales to dispensaries in Nevada.

Innovent Biologics, Inc. today presented clinical research data on cohort E from a Phase Ib clinical trial at the International Association for the Study of Lung Cancer (IASLC) Asia Conference on Lung Cancer 2018 (#ACLC18).

National HealthCare Corporation announced today that it will pay a quarterly dividend of 50 cents per common share to shareholders of record on December 31, 2018 and payable on March 1, 2019.

Exact Sciences Corp. today announced that company management will be presenting at the following investor conference during November and invited investors to participate by webcast.